Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Cost of Revenue (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Cost of Revenue data on record, last reported at $7.3 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 314.73% year-over-year to $7.3 million; the TTM value through Oct 2025 reached $19.4 million, down 17.04%, while the annual FY2025 figure was $7.5 million, 74.34% down from the prior year.
  • Cost of Revenue reached $7.3 million in Q4 2025 per CSBR's latest filing, down from $8.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $18.1 million in Q2 2024 and bottomed at -$2.5 million in Q2 2025.
  • Average Cost of Revenue over 5 years is $5.6 million, with a median of $5.9 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: soared 1500.55% in 2021, then plummeted 113.8% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $5.6 million in 2021, then surged by 32.7% to $7.4 million in 2022, then plummeted by 75.88% to $1.8 million in 2023, then decreased by 2.45% to $1.8 million in 2024, then surged by 314.73% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $7.3 million in Q4 2025, $8.0 million in Q3 2025, and -$2.5 million in Q2 2025.